Stockreport

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Sionna Therapeutics, Inc.  (SION) 
PDF Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on trac [Read more]